as 11-12-2024 4:00pm EST
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
Founded: | 2004 | Country: | United States |
Employees: | N/A | City: | ALAMEDA |
Market Cap: | 7.0B | IPO Year: | 2015 |
Target Price: | $231.08 | AVG Volume (30 days): | 410.9K |
Analyst Decision: | Buy | Number of Analysts: | 14 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.89 | EPS Growth: | -15.96 |
52 Week Low/High: | $148.00 - $277.34 | Next Earning Date: | 10-30-2024 |
Revenue: | $1,163,776,000 | Revenue Growth: | 16.96% |
Revenue Growth (this year): | 13.65% | Revenue Growth (next year): | 14.38% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Elsesser Adam | PEN | CEO and President | Oct 21 '24 | Sell | $204.71 | 15,000 | $3,068,366.75 | 877,082 | |
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Oct 1 '24 | Sell | $191.07 | 600 | $114,455.67 | 61,067 | |
Kassing Don W. | PEN | Director | Oct 1 '24 | Sell | $193.93 | 170 | $32,968.10 | 835 | |
Elsesser Adam | PEN | CEO and President | Sep 20 '24 | Sell | $197.63 | 15,000 | $2,965,646.17 | 877,082 | |
Grewal Harpreet | PEN | Director | Sep 4 '24 | Sell | $204.11 | 782 | $159,614.02 | 8,863 | |
Roberts Johanna | PEN | EVP, Gen. Counsel & Secretary | Sep 3 '24 | Sell | $206.04 | 600 | $123,732.57 | 61,067 | |
Elsesser Adam | PEN | CEO and President | Aug 22 '24 | Sell | $203.50 | 30,000 | $6,095,597.02 | 877,082 |
PEN Breaking Stock News: Dive into PEN Ticker-Specific Updates for Smart Investing
Simply Wall St.
6 days ago
Clinical Trials Arena
6 days ago
Argus Research
7 days ago
Zacks
7 days ago
Zacks
8 days ago
PR Newswire
8 days ago
Zacks
9 days ago
Simply Wall St.
11 days ago
The information presented on this page, "PEN Penumbra Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.